# Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects

> **NCT02567682** · PHASE1 · COMPLETED · sponsor: **Global Blood Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** GBT440

## Key facts

- **NCT ID:** NCT02567682
- **Lead sponsor:** Global Blood Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567682, "Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02567682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*